Cite
HARVARD Citation
Trillsch, F. et al. (n.d.). 2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. International journal of gynecological cancer. p. A268. [Online].